Cargando…

Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience

Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world set...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yue (Jennifer), Fu, Rui, Levinsky, Justin T., Kamalraj, Pabiththa, Chan, Kelvin K. W., Parmar, Ambica, Eskander, Antoine, Smoragiewicz, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604932/
https://www.ncbi.nlm.nih.gov/pubmed/37887545
http://dx.doi.org/10.3390/curroncol30100645
_version_ 1785126953004564480
author Du, Yue (Jennifer)
Fu, Rui
Levinsky, Justin T.
Kamalraj, Pabiththa
Chan, Kelvin K. W.
Parmar, Ambica
Eskander, Antoine
Smoragiewicz, Martin
author_facet Du, Yue (Jennifer)
Fu, Rui
Levinsky, Justin T.
Kamalraj, Pabiththa
Chan, Kelvin K. W.
Parmar, Ambica
Eskander, Antoine
Smoragiewicz, Martin
author_sort Du, Yue (Jennifer)
collection PubMed
description Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1–2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC.
format Online
Article
Text
id pubmed-10604932
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106049322023-10-28 Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience Du, Yue (Jennifer) Fu, Rui Levinsky, Justin T. Kamalraj, Pabiththa Chan, Kelvin K. W. Parmar, Ambica Eskander, Antoine Smoragiewicz, Martin Curr Oncol Communication Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1–2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC. MDPI 2023-09-29 /pmc/articles/PMC10604932/ /pubmed/37887545 http://dx.doi.org/10.3390/curroncol30100645 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Du, Yue (Jennifer)
Fu, Rui
Levinsky, Justin T.
Kamalraj, Pabiththa
Chan, Kelvin K. W.
Parmar, Ambica
Eskander, Antoine
Smoragiewicz, Martin
Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
title Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
title_full Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
title_fullStr Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
title_full_unstemmed Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
title_short Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
title_sort nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective tertiary centre’s real-world experience
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604932/
https://www.ncbi.nlm.nih.gov/pubmed/37887545
http://dx.doi.org/10.3390/curroncol30100645
work_keys_str_mv AT duyuejennifer nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience
AT furui nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience
AT levinskyjustint nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience
AT kamalrajpabiththa nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience
AT chankelvinkw nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience
AT parmarambica nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience
AT eskanderantoine nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience
AT smoragiewiczmartin nivolumabforrecurrentormetastaticheadandnecksquamouscellcarcinomaaretrospectivetertiarycentresrealworldexperience